SeaDragon Annual Report 2014-2015
30 June 2015. Link here. SeaDragon annual report, including audited financial statements, for the year to 31 March 2015.
Archive for month: June, 2015
SeaDragon streamlines Board
/in Portfolio Companies, SeaDragonSEA: NZX and Media Release 29 June 2015. Link here. Board reduced to five with focus on supply chain and production; outgoing CEO named Honorary President SeaDragon Limited (NZX:SEA) today announces a number of Director changes as it adds production and supply chain management experience to the Board in preparation for the company’s move into the […]
SeaDragon raises up to $2.5M with convertible loan
/in Portfolio Companies, SeaDragon9:53am, 24 Jun 2015 SEA: NZX and Media Release 24 June 2015 Link here. SeaDragon raises up to $2.5M with convertible loan; signals capital raising Richard Alderton appointed Interim Chief Executive Officer SeaDragon Limited (NZX:SEA) today announces that one of its cornerstone shareholders, BioScience Managers, has agreed to advance the company up to NZ$2.5 million via […]
Adherium Receives ISO 13485 Certification
/in Adherium, Portfolio CompaniesJune 16, 2015 Link here – Adherium (NZ) Limited (formerly Nexus6) has received ISO 13485 medical device quality management system certification for operations at its New Zealand head office. ISO 13485 is an international quality management standard that covers all aspects of a medical device company’s operations from product development to manufacturing to customer support. It has […]
Rex Bionics plc – Proposed Fundraising and Notice of General Meeting
/in Portfolio Companies, Rex BionicsPlacing and Subscription to raise £2.1 million and proposed Additional Fundraising to raise approximately £1.0 million and Share Restructuring. Link here. 12 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces a proposed Placing and Subscription of 3,500,000 New Ordinary Shares at […]
AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization
/in Portfolio CompaniesResults presented at the 38th European Cystic Fibrosis Conference Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 12, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. […]
SeaDragon Full Year Result to 31 March 2015
/in Portfolio Companies, SeaDragonFINANCIAL RESULTS FOR THE 12 MONTHS TO 31 MARCH 2015. Link here. SeaDragon annual sales double; Omega 3 refinery on track for start-up in Q4 2015 Highlights: • New Omega 3 fish oil refinery on track for commissioning later this year, realising a 10 year strategic plan • Additional Squalene raw material supply contracts position SeaDragon for […]
AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage
/in Portfolio CompaniesResults to be presented at the 38th European Cystic Fibrosis Conference. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 8, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of […]
Nexvet Advances Manufacturing Strategy
/in Portfolio CompaniesNexvet Advances Manufacturing Strategy. Link here. Agreement signed with FUJIFILM Diosynth Biotechnologies Key appointment made in Ireland DUBLIN, Ireland and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, announced today an update to its manufacturing strategy. Nexvet has signed a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to provide […]
Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including […]
© BioScience Managers, all rights reserved